NeoGenomics, Inc. (NASDAQ:NEO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $19.78.
A number of analysts have commented on NEO shares. Craig Hallum started coverage on shares of NeoGenomics in a research note on Wednesday, May 1st. They set a “buy” rating and a $26.00 price target for the company. Needham & Company LLC cut their price target on shares of NeoGenomics from $24.00 to $19.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. BTIG Research cut their price target on shares of NeoGenomics from $23.00 to $21.00 and set a “buy” rating on the stock in a report on Thursday, May 2nd. Benchmark restated a “buy” rating and issued a $18.00 price objective on shares of NeoGenomics in a research note on Wednesday, May 1st. Finally, TD Cowen lowered their price objective on NeoGenomics from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st.
Get Our Latest Stock Report on NEO
Institutional Inflows and Outflows
NeoGenomics Stock Performance
NASDAQ:NEO opened at $13.73 on Wednesday. The company has a market capitalization of $1.75 billion, a PE ratio of -20.80 and a beta of 1.19. The company has a 50 day simple moving average of $14.08 and a two-hundred day simple moving average of $15.11. The company has a debt-to-equity ratio of 0.58, a quick ratio of 7.22 and a current ratio of 7.48. NeoGenomics has a fifty-two week low of $11.03 and a fifty-two week high of $21.22.
NeoGenomics (NASDAQ:NEO – Get Free Report) last released its quarterly earnings data on Tuesday, April 30th. The medical research company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). The company had revenue of $156.24 million during the quarter, compared to the consensus estimate of $149.82 million. NeoGenomics had a negative net margin of 13.79% and a negative return on equity of 3.54%. Research analysts anticipate that NeoGenomics will post -0.21 earnings per share for the current year.
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Further Reading
- Five stocks we like better than NeoGenomics
- Where to Find Earnings Call Transcripts
- RXO Shares Surge Following New Acquisition Deal
- 3 Stocks to Consider Buying in October
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Stock Dividend Cuts Happen Are You Ready?
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.